MZ-J-7-138

GHRH antagonist; Phe(4-Cl) is 4-chlorophenylalanine; Tyr(Et) is O-ethyltyrosine; Abu is a-aminobutyric acid; Nle is norleucine; Har is homoarginine; Orn is ornithine

Also Known As:

(CH3-(CH2)6-CO-Tyr1,DArg 2,Phe(4-C1)6,Ala8,His9, Tyr(Et)10,His11,Orn12,Abu15, His20, Orn21,Nle27,D-Arg28,Har29)hGHRH(1-29)NH2

Networked: 5 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Halmos, Gabor: 5 articles (04/2012 - 07/2005)
2.	Schally, Andrew V: 5 articles (04/2012 - 07/2005)
3.	Varga, Jozsef L: 5 articles (04/2012 - 07/2005)
4.	Zarandi, Marta: 4 articles (04/2012 - 07/2005)
5.	Rick, Ferenc G: 3 articles (04/2012 - 09/2006)
6.	Groot, Kate: 3 articles (12/2008 - 07/2005)
7.	Heinrich, Elmar: 3 articles (12/2008 - 09/2006)
8.	Stangelberger, Anton: 2 articles (04/2012 - 09/2007)
9.	Buchholz, Stefan: 2 articles (12/2008 - 09/2006)
10.	Hohla, Florian: 2 articles (12/2008 - 09/2006)

Related Diseases

1.	Prostatic Neoplasms (Prostate Cancer) 12/01/2008 - "Our results demonstrate the efficacy of GHRH antagonist MZ-J-7-138 in suppressing growth of PC-3 prostate cancer at doses lower than previous antagonists. " 04/01/2012 - "Nude mice bearing xenografted PC-3, DU-145, and MDA-PCa-2b human prostate cancer lines were treated with a new potent GHRH antagonist MZ-J-7-138. " 04/01/2012 - "To determine whether tumor inhibition by MZ-J-7-138 involves apoptotic mechanisms such as p53 and p21, we evaluated by Western Blot the expression of mutant mt-p53 in PC-3 and DU-145 and of wild type (wt-p53) in MDA-PCa-2b prostate cancers as well as p21. " 12/01/2008 - "Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138." 04/01/2012 - "Our findings indicate that the anti-proliferative effects of GHRH antagonist MZ-J-7-138 and LHRH antagonist Cetrorelix on prostate cancers involve p53 and p21 signaling."
2.	Neoplasms (Cancer) 12/01/2008 - "Treatment with 2.5, 5, and 10 microg/day MZ-J-7-138 caused a significant dose-dependent growth reduction of PC-3 tumors. " 04/01/2012 - "To determine whether tumor inhibition by MZ-J-7-138 involves apoptotic mechanisms such as p53 and p21, we evaluated by Western Blot the expression of mutant mt-p53 in PC-3 and DU-145 and of wild type (wt-p53) in MDA-PCa-2b prostate cancers as well as p21. " 09/26/2006 - "In other experiments, treatment with MZ-J-7-138 or docetaxel reduced tumor volume of s.c. " 07/26/2005 - "Treatment with MZ-5-156 and MZ-J-7-138 significantly (P < 0.05) inhibited the growth of RL and HT tumors by 59.9-73.9%. " 04/01/2012 - "The expression of mutant (mt-p53) and p21 protein in PC-3 and DU-145 tumors was significantly decreased by treatment with MZ-J-7-138, whereas wild type wt-p53 expression in MDA-PCA-2b tumors was up regulated by treatment with Cetrorelix. "
3.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 09/26/2006 - "We investigated the effect of antagonists of growth hormone-releasing hormone (GHRH) MZ-J-7-138 and JV-1-92 on H460 human non-small cell lung carcinoma (NSCLC) xenografted orthotopically into nude mice. "

Related Drugs and Biologics

1.	Proteins (Proteins, Gene)
2.	Gonadotropin-Releasing Hormone (GnRH)
3.	Androgens
4.	cetrorelix (Cetrotide)
5.	Intercellular Signaling Peptides and Proteins (Growth Factors)
6.	Growth Hormone-Releasing Hormone (Somatotropin Releasing Hormone)
7.	Insulin-Like Growth Factor II (Somatomedin A)
8.	Docetaxel (Taxotere)
9.	MZ-J-7-118
10.	MZ 5-156

Related Therapies and Procedures

1.	Therapeutics
2.	Castration